Futura Medical PLC
LSE:FUM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.5
45.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Futura Medical PLC
Futura Medical PLC
Net Income (Common)
Futura Medical PLC
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Futura Medical PLC
LSE:FUM
|
Net Income (Common)
-£3.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-3%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Net Income (Common)
£4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Net Income (Common)
$6.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
12%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Net Income (Common)
-$153.7m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Net Income (Common)
$285m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Net Income (Common)
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Futura Medical PLC
Glance View
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
See Also
What is Futura Medical PLC's Net Income (Common)?
Net Income (Common)
-3.8m
GBP
Based on the financial report for Jun 30, 2024, Futura Medical PLC's Net Income (Common) amounts to -3.8m GBP.
What is Futura Medical PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%
Over the last year, the Net Income (Common) growth was 27%. The average annual Net Income (Common) growth rates for Futura Medical PLC have been -9% over the past three years , 15% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
